Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gene mutation may amplify cognitive risks of brain stimulation in Parkinson's

NCT ID NCT03234478

Completed Knowledge-focused Sponsor: Rutgers, The State University of New Jersey Source: ClinicalTrials.gov ↗

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This study investigates whether Parkinson's disease patients who carry a mutation in the GBA gene are more likely to experience cognitive decline after deep brain stimulation (DBS) surgery. Researchers will compare thinking and memory test results in 150 patients with and without the mutation, both before and after DBS placement. The goal is to understand how genetics and DBS together affect long-term brain function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
deep brain stimulation (DBS) of the subthalamic nucleus
What this could lead to
If it works, this could help doctors predict which Parkinson's patients are at higher risk for cognitive decline after DBS surgery, allowing for more personalized treatment decisions.
What could go wrong
This is an observational study, not a treatment trial, so it won't test a new therapy. The results may only apply to people with specific genetic mutations and may not lead to immediate changes in care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COGNITIVE DECLINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction inherited disease susceptibility Parkinson disease parkinsonian disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COGNITIVE DECLINE GBA GENE MUTATION GENETIC PREDISPOSITION PARKINSON PARKINSON DISEASE

Contacts and locations

Locations

  • Rutgers-Robert Wood Johnson Medical School

    New Brunswick, New Jersey, 08901, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.